|
 Welcome to D-Gen Limited
D-Gen is a research-based bio-medical company which innovates in the field of prion-related disease by identifying, developing and exploiting proprietary diagnostic and therapeutic targets and technologies. D-Gen is committed to utilising the latest research in developing products and services that meet the global animal and public health challenge posed by prion and other neurodegenerative diseases.
D-Gen was formed in May 2000 as a University spin-out company to commercialise relevant research emanating from the work of Professor John Collinge's team at the Medical Research Council (MRC) Prion Unit (now based at the Institute of Neurology, University College London). The MRC Prion Unit was set up to create an international centre of excellence. It plays a key role in linking basic science to clinical research and has contributed to some of the most significant advances in the field of prion diseases. These include:
-
producing the first experimental evidence of a link between BSE and CJD
-
replicating the conversion of normal prion protein into the abnormal, disease associated type in the laboratory using a genetically engineered form of the prion protein
-
developing a novel test to detect abnormal prion protein in human tonsils and to diagnose vCJD in vivo
-
developing methods for prion decontamination of surgical instruments
-
showing that monoclonal antibodies could form the basis of future medicine to treat CJD.
D-Gen's shareholders include Imperial Innovations, Medical Research Council, Wellcome Trust, University of Bristol and a number of inventor scientists.
Find out how we can help you...
Our Technologies
Our Products
Download brochure :
"Innovating Technologies: Meeting the Prion Challenge"
|
